Clinical outcomes of zotarolimus-eluting stents versus the first generation sirolimus-eluting stents and paclitaxel-eluting stents: A meta-analysis of randomized trials

International Journal of Cardiology

Volumn 157, Issue 1, 2012, Pages 152-156

  Wei, Gao ^a   Fang, Yuan ^a   Yaqi, Ren ^a   Lin, Chen ^a   Ningfu, Wang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Paclitaxel eluting stent; Randomized controlled trial; Sirolimus Eluting Stents; Zotarolimus eluting stent

Indexed keywords

PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ADULT; BARE METAL STENT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; STENT THROMBOSIS;

EID: 84860233075     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.020     Document Type: Article

References (23)

1. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxeleluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
2. A.A. Bavry, D.J. Kumbhani, T.J. Helton, P.P. Borek, G.R. Mood, and D.L. Bhatt Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 119 2006 1056 1061
3. D.E. Kandzari, M.B. Leon, J.J. Popma, and P.J. Fitzgerald Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial J Am Coll Cardiol 48 12 2006 2440 2447
4. M.B. Leon, D.E. Kandzari, and E.L. Eisenstein Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 2 12 2009 1208 1218
5. M.B. Leon, L. Mauri, and J.J. Popma A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 6 2010 543 554
6. K. Rasmussen, M. Maeng, and A. Kaltoft Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 9720 2010 1090 1099
7. R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents J Am Coll Cardiol 55 23 2010 2536 2543
8. D.W. Park, Y.H. Kim, and S.C. Yun Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 15 2010 1187 1195
9. M.B. Leon, E. Nikolsky, D.E. Cutlip, and L. Mauri Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial JACC Cardiovasc Interv 3 10 2010 1043 1050
10. D.E. Kandzari, L. Mauri, and J.J. Popma Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 4 5 2011 543 550
11. Gray WA, Yeung AC, Cutlip DE, et al. A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trial. Int J Cardiol in press [Electronic publication ahead of print 2011 Jun 7].
12. A. Kastrati, J. Mehilli, and J. Pache Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 1030 1039
13. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
14. A.J. Nordmann, M. Briel, and H.C. Bucher Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis Eur Heart J 27 2006 2784 2814
15. B. Lagerqvist, S.K. James, U. Stenestrand, J. Lindback, T. Nilsson, and L. Wallentin Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
16. N. Kukreja, Y. Onuma, and P.W. Serruys Xience V everolimus-eluting coronary stent Expert Rev Med Devices 6 2009 219 229
17. A. de Waha, A. Dibra, R.A. Byrne, and G. Ndrepepa Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials Circ Cardiovasc Interv 4 4 2011 371 377
18. S. Cassese, R. Piccolo, G. Galasso, R. De Rosa, and F. Piscione Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimuseluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials Int J Cardiol 150 2011 84 89
19. H. Takagi, and T. Umemoto An updated meta-analysis of randomized controlled trials of everolimus- versus paclitaxel-eluting stents Int J Cardiol 151 3 2011 354 355
20. P.W. Serruys, S. Silber, and S. Garg Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2 2010 136 146
21. G.G. Stefanini, P.W. Serruys, and S. Silber The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention) J Am Coll Cardiol 57 22 2011 2221 2232
22. J.A. Herrador, J.C. Fernandez, M. Guzman, and V. Aragon Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions Catheter Cardiovasc Interv 78 7 2011 1086 1092
23. A.J.S. Coats, and L.G. Shewan Statement on authorship and publishing ethics in the International Journal of Cardiology Int J Cardiol 153 2011 239 240